Mineralys Therapeutics, Inc. (MLYS) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for Mineralys Therapeutics, Inc. (MLYS): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 33/100 — a percentile rank of Mineralys Therapeutics, Inc.’s fundamentals against Manufacturing peers, weakest on profitability. A quality ranking, not a price prediction.
| Market cap | $2.1B |
| EV / EBITDA | -5.5× |
| Return on equity | -63.4% |
| ROIC | -72.7% |
| Debt / equity | 0.2× |
| Dividend yield | 0.0% |
Is Mineralys Therapeutics, Inc. overvalued? P/B looks fair vs its 5-year range.
Independent of the events above — derived from Mineralys Therapeutics, Inc.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact